Luke Beshar

Luke M.
Beshar currently works at Protara Therapeutics, Inc., as Chairman from 2020, Inotrem SA, as Chairman from 2021, Fluorinov Pharmaceuticals, Inc., as Director from 2015, and New York State Society of Certified Public Accountants, as Member.
Mr. Beshar also formerly worked at Entera Bio Ltd., as Chairman from 2016 to 2018, ArTara Subsidiary, Inc., as Chairman, PNY Technologies, Inc., as Director, Trillium Therapeutics, Inc., as Independent Director from 2014 to 2021, REGENXBIO, Inc., as Independent Director from 2015 to 2021, Sancilio & Co., Inc., as Director, Sancilio Pharmaceuticals Co., Inc., as Director, Omega Therapeutics, Inc., as Independent Director from 2021 to 2024, Cambrex Corp., as Chief Financial Officer & Executive Vice President from 2002 to 2007, The Genlyte Group, Inc., as Chief Financial Officer, NPS Pharmaceuticals, Inc., as Chief Financial Officer & Executive Vice President from 2012 to 2015, Dendrite International, Inc., as Chief Financial Officer & Senior Vice President in 2002, WSR Corp, as Chief Financial Officer, and Exp@nets, Inc., as Chief Financial Officer & Executive Vice President from 1998 to 2002.
Mr. Beshar received his undergraduate degree from Michigan State University.